After mulling over the data from a failed phase 2 trial, Johnson & Johnson has decided to halt development of its Addex Therapeutics-partnered epilepsy drug, Fierce Biotech has learned. The positive ...
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued ...
Addex Therapeutics’ attempt to expand use of dipraglurant into muscle spasms has stumbled at the first hurdle. A phase 2a clinical trial of the mGluR5 negative allosteric modulator has delivered ...
Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149 ...
Geneva, Switzerland, November 11, 2024-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...
Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique ...
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Addex Therapeutics ( (CH:ADXN)) has ...
Geneva, Switzerland and New York, USA, April 3, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, ...
Geneva, Switzerland, April 17, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results